Perspectum
Delivers cutting-edge, digital technologies to help clinicians provide better patient care
🤖
AI Overview
With $230K in lobbying spend across 7 quarterly filings, Perspectum is an active lobbying client. Their lobbying covers 4 issue areas. Active from 2021 to 2022.
$230K
Total Spend
2
Years Active
1
Firms Hired
1
Lobbyists Deployed
4
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $150K |
| 2022 | $80K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, MED, Medicare/Medicaid, Budget/Appropriations
- •Funding for NIH and CDC programs dealing with COVID and long-COVID research and service delivery.
- •Food and Drug Administration regulation of medical devices, including Emergency Use Authorizations for critical products during the COVID-19 crisis.
- •Reimbursement of new technologies in Medicare, including the Medicare Coverage of Innovative Technology Program.
- •Issues associated with diagnosing and treating the effects of COVID-19 appropriately (no specific legislation). Commission to study COVID-19 (draft Menendez proposal, no bill number yet)
- •Funding for research and clinical trials related to long term studies of COVID-19 at the National Institutes of Health provided in the Consolidated Appropriations Act of 2021 (PL 116-260).
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.